Regorafenib and Durvalumab for the Treatment of High-Risk Liver Cancer
Regorafenib and Durvalumab for the Treatment of High-Risk Liver Cancer
Active, not recruiting · NCT05194293 · Registry updated 2026-07-20Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Regorafenib and Durvalumab for the Treatment of High-Risk Liver Cancer | Digestive System Diseases, Digestive System Neoplasms, Liver Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, adenocarcinoma, carcinoma, epithelial neoplasm, hepatocellular carcinoma, liver disorder, neoplasm | Active, not recruiting | Phase 2 | 2026-07-20 | NCT05194293 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Academic and Community Cancer Research United | 13 |
| National Cancer Institute (NCI) | 3015 |
3 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Emory University Hospital/Winship Cancer Institute | Atlanta | United States | 299 |
| Medical College of Wisconsin | Milwaukee | United States | 483 |
| University of Alabama at Birmingham Cancer Center | Birmingham | United States | 186 |